Impact of drug resistance mutations on virologic response to salvage therapy

AIDS

Volumn 13, Issue 2, 1999, Pages

  Lorenzi, Patrizio ^a   Opravil, Milos ^b   Hirschel, Bernard ^a   Chave, Jean Philippe ^c   Furrer, Hans Jacob ^d   Sax, Hugo ^b   Perneger, Thomas Vaclav ^a   Perrin, Luc ^a   Kaiser, Laurent ^a   Yerly, Sabine ^a   Battegay, M ^c   Bernasconi, E ^c   Burgisser Ph ^c   Egger, M ^c   Erb, P ^c   Fierz, W ^c   Flepp, M ^c   Francioli, P ^e   Furrer, H J ^c   Grob, P ^c   Ledergerber, B ^c   Malinverni, R ^c   Matter, L ^c   Paccaud, F ^c   Pantalco, G ^c   Pichler, W ^c   Piffaretti, J C ^c   Rickenbach, M ^c   Sudre, P ^c   Schupbach, J ^c   Telenti, A ^c   Vernazza, P ^c   more..

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c University Hospital ^*

^d UNIVERSITY OF BERN   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Nelfinavir; Resistance mutations; Salvage therapy

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG RESISTANCE; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SALVAGE THERAPY; VIRUS GENE;

ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, MICROBIAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY;

EID: 0033009094     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199902040-00001     Document Type: Article

References (16)

1. Fätkenheuer G, Theisen A, Rockstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
2. Lorenzi P, Yerly S, Abderrakim K, et al.: Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 1997, 12:F95-F99.
3. Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S: Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998, 12:F97-F102.
4. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD: Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997, 126:939-945.
5. Coombs RW, Welles SL, Hooper C, et al.: Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996, 174:704-712.
6. Fiscus SA, Hughes MD, Lathey JI., et al.: Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. J Infect Dis 1998, 177:625-633.
7. Schinazi RF, Larder BA, Mellors J: Resistance table: mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997, 5:129-142.
8. Hirsch MS, Conway B, D'Aquila RT, et al.: Antiretroviral drug resistance testing in adults with HIV infection. JAMA 1998, 279:1984-1991.
9. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
10. Roberts NA, Craig JC, Sheldon J: Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. AIDS 1998, 12:453-460.
11. Patick AK, Kuritzkes D, Johnston VA, et al.: Genotypic and phenotypic analyses of HIV-1 variants isolated from patients treated with nelfinavir and other HIV-1 protease inhibitors. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, Florida, June 1997 [abstract 18].
12. Yerly S, Rakik A, Kinloch-de Loës S, et al.: Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 1998, 72:3520-3523.
13. McHomey CA, Ware JE, Raczek AE: The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health construct. Med Care 1993, 31:247-263.
14. De Jong JJ. Jurriaans S, Goudsmit J. et al.: Insertion of two amino acids in reverse transcriptase (RT) during antiretroviral combination therapy: implications for resistance against nucleoside RT inhibitors. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. Lake Maggiore, Italy, June 1998 [abstract 18].
15. Herlogs K, Kemp S, Bloor S, et al.: Pattern of cross-resistance among protease inhibitors in over 1500 clinical HIV-1 isolates. Comparison of genotypic and phenotypic resistance profiles. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradiction. Lake Maggiore, Italy, June 1998 [abstract 70].
16. Sommadossi JP, Valantin MA, Zhou XJ, et al.: Intracellular phosphorylation of stavudine (d4T) and 3TC correlates with their antiviral activity in naive and zidovudine (ZDV) experienced HIV-infected patients. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 362].